Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
우리나라 폐동맥고혈압환자에 대한 Bosentan과 Iloprost의 비용-효용 분석Cost-Utility Analysis of Bosentan Versus Iloprost in Korean Patients with Pulmonary Arterial Hypertension
- Other Titles
- Cost-Utility Analysis of Bosentan Versus Iloprost in Korean Patients with Pulmonary Arterial Hypertension
- Issue Date
- Apr-2010
- Publisher
- 대한약학회
- Keywords
- cost-effectiveness; cost-utility; pulmonary arterial hypertension; bosentan; iloprost
- Citation
- 약 학 회 지, v.54, no.2, pp 126 - 133
- Pages
- 8
- Journal Title
- 약 학 회 지
- Volume
- 54
- Number
- 2
- Start Page
- 126
- End Page
- 133
- ISSN
- 0377-9556
- Abstract
- This study was conducted to analyze cost-utility of bosentan versus iloprost indicated for pulmonary arterial hypertension (PAH) in a Korean healthcare setting from a payer’s perspective. We constructed a Markov model to estimate total costs and outcomes for 1-year time horizon in a hypothetical cohort of 50-year-old patients with PAH. Base analysis showed that bosentan resulted in KW 5.5 billions saving and 18 quality-adjusted life year (QALY) gains per 100 patients compared to iloprost. Bosentan as a dominant strategy was found to be robust through various sensitivity analyses.
- Files in This Item
- Go to Link
- Appears in
Collections - 약학대학 > 약학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.